Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Phase 2, randomised, double-blind,double-dummy study in hospitalised adults with complicated
urinary tract infection (cUTI), including acute pyelonephritis.Treatment duration for each
cohort was 7 to 14 days. Patients were not permitted to switch to oral therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Meropenem Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam